Immunovant, Inc. IMVT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

47/100

2/6 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Immunovant, Inc. (IMVT) generated $-92.33M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $-92.33M.

Cash conversion ratio was 0.83x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (40/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.83x suggests some earnings are non-cash items

Overall SharesGrow Score: 46/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

47/100

SG Score

View full scorecard →

VALUE

43/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

85/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

40/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Immunovant, Inc. Cash Flow History

Metric	TTM	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025
Operating Cash Flow	$-422.89M	$-92.33M	$-102.52M	$-117.41M	$-110.64M
Capital Expenditure	$-201K	$0.00	$0.00	$0.00	$-201K
Free Cash Flow	$-423.09M	$-92.33M	$-102.52M	$-117.41M	$-110.84M